Easter 2017 Enrolment Closure
To ensure the safe and complete enrolment of patients into our
Warfarin Care program, enrolments will be closed between the
Community patients: Closing 5pm
Thursday 30 March 2017 and re-opening 9am Tuesday 18 April
Hospital patients: Closing 5pm
Monday 3 April 2017 and re-opening 9am Tuesday 18 April 2017.
Warfarin Care Enrolment and Procedure
Sullivan Nicolaides Pathology's Warfarin Care program is a
service provided to patients of Sullivan Nicolaides Pathology's
regular referring doctors.
For patient safety reasons, we will not accept patients
into our Warfarin Care program where we do not have regular
communications with the patient's general
This precludes patients of general practitioners who do
not usually refer to Sullivan Nicolaides Pathology and patients
directly from public hospitals. Sullivan Nicolaides Pathology
reserves the right to refuse enrolment of any patient for patient
Before enrolment, please assess your patient's eligilibility for
our Warfarin Care program according to our Enrolment
& Eligibility criteria below.
PLEASE FAX THE COMPLETED FORM TO (07) 3377 8461
Enrolment Form - Interactive PDF document
Patient Guide - PDF document
Program Billing Information - PDF document
Warfarin Care Discharge Summary - PDF document
Warfarin Care SMS Patient Registration Brochure - PDF
Warfarin Care Investigative Protocols
Links of Interest
Please read the below carefully before enrolling your
patient in the Warfarin Care program.
For more information, please contact Warfarin Care on Ph
(07) 3377 8578 or Fax (07) 3377 8461.
Step 1 - Before enrolment, please:
- assess your patient's eligibility for our Warfarin Care program
according to our Eligibility criteria.
- provide your patient with adequate dosing instructions until
Warfarin Care Support have notified you and your patient that the
enrolment process is complete. Allow at least 3 working days.
Step 2 - Doctor, nurse, or practice manager
must fax the completed enrolment application to Warfarin Care
Support to enrol your patient. Please retain this original
enrolment application for future reference.
Your patient's eligibility will be assessed and we
will notify you if our program is not suitable for your
The referring doctor must manage the patient's heparin therapy,
including low molecular weight heparin such as Clexane. Heparin
therapy (UF or LMWH) should continue until INR is in the
therapeutic range for at least 48 hours.
We cannot commence enrolments on Fridays, weekends, or
public holidays. Enrolment days will be
limited prior to Easter, Christmas and New Year to allow the safe
transfer of your patient onto our program.
Enrolment in our Warfarin Care program is contingent upon all
parties - doctor, patient, and laboratory - understanding and
accepting their roles and responsibilities as outlined in the
Sullivan Nicolaides Pathology Handbook for Doctors.
To be eligible for enrolment on our program, your patient
- be taking Warfarin (not Dindevan medication)
- have a minimum enrolment period of one month
- have a General Practitioner who refers their patients to
Sullivan Nicolaides Pathology
- have a valid contact phone number and mailing address
- be able to comprehend and record verbal dose instructions
- be able to comply with dose instructions (or has a carer who
- be able to attend for testing on scheduled dates, subject to
- not have been discharged from a Warfarin Care program due to
- not require a narrow target range (less than one unit)
- not require daily INR levels
- not require acute care
|ONGOING PATIENT ELIGIBILITY FOR WARFARIN
Patients who were eligible on enrolment will become ineligible
for our Warfarin Care program if they:
- require a narrow target range
- require daily INR levels
- are non-compliant
- become unable to follow verbal or written dose
- are abusive to Sullivan Nicolaides Pathology staff
- develop complex clinical conditions or become unstable where
one-on-one management by their own referring doctor is
- experience ongoing difficulties attending on scheduled test
dates - for example, patients who reside in remote areas or whose
employment requires frequent travel
You will be advised of our concerns regarding your patient's
suitability for our program. If these concerns are not resolved,
then we will return the responsibility for managing your patient's
Warfarin therapy to you.
Website - The Australasian Society of Thrombosis and